Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 3/20 | 0.50 |
| ▸ | MAOA | P21397 | 2/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.43 |
| ▸ | NAMPT | P43490 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14261828 | 1.00 | MAOB (0.50) | MAOBMAOAALOX15TSHRHSD17B10 | |
| SCHEMBL6011036 | 0.91 | ALOX15 (0.50) | MAOBALOX15TSHRHSD17B10ALDH1A1 | |
| SCHEMBL6012010 | 0.88 | TSHR (0.48) | MAOBALOX15TSHRHSD17B10MAPT | |
| SCHEMBL14261815 | 0.88 | MAOB (0.50) | MAOBALOX15TSHRHSD17B10MAPT | |
| SCHEMBL6011774 | 0.88 | ALDH1A1 (0.53) | MAOBMAOAALOX15TSHRHSD17B10 | |
| SCHEMBL6011051 | 0.88 | ALOX15 (0.48) | MAOBALOX15TSHRHSD17B10ALDH1A1 | |
| SCHEMBL2718661 | 0.88 | MAOB (0.50) | MAOBMAOAALOX15TSHRHSD17B10 | |
| SCHEMBL2718666 | 0.88 | MAOB (0.50) | MAOBMAOAALOX15TSHRHSD17B10 | |
| SCHEMBL6012034 | 0.88 | MAOB (0.50) | MAOBMAOAALOX15TSHRHSD17B10 | |
| SCHEMBL10069198 | 0.88 | TSHR (0.50) | MAOBMAOAALOX15TSHRHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1785415-B1 | PIPERIDINE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | ASTELLAS PHARMA INC (JP) | 2012-05-02 | — | — | EP | disclosed |
| US-20080070898-A1 | Piperidine Derivative or Pharmaceutically Acceptable Salt Thereof | ASTELLAS PHARMA INC. (JP) | 2008-03-20 | — | — | US | disclosed |
| US-20080070898-A1 | Piperidine Derivative or Pharmaceutically Acceptable Salt Thereof | ASTELLAS PHARMA INC. (JP) | 2008-03-20 | — | — | US | disclosed |
| EP-1785415-A1 | PIPERIDINE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | Astellas Pharma Inc. (JP) | 2007-05-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080070898-A1 | Piperidine Derivative or Pharmaceutically Acceptable Salt Thereof | TRPV1, TRPA1, CACNA1D | MAOB 3198/4885MAOA 3281/4885ALOX15 1198/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.